Cite
HARVARD Citation
Sun, R. et al. (2022). Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. Journal for immunotherapy of cancer. 10 (10), p. . [Online].